{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:59:05Z","timestamp":1787162345059,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ghir.2024.101628","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T18:20:51Z","timestamp":1731262851000},"page":"101628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Identification and differentiation of somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone in equine plasma by LC-HRMS for doping control purpose"],"prefix":"10.1016","volume":"80","author":[{"given":"Yoshibumi","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Sugai-Bannai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Hirano-Kodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary Ngai-Wa","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ghir.2024.101628_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrendo.2018.22","article-title":"Growth hormone - past, present and future","volume":"14","author":"Ranke","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2024.101628_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1521-0391.2010.00093.x","article-title":"Human growth hormone abuse in male weightlifters","volume":"20","author":"Brennan","year":"2011","journal-title":"Am. J. Addict."},{"issue":"2","key":"10.1016\/j.ghir.2024.101628_bb0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2011-1035","article-title":"Growth hormone doping in sports: a critical review of use and detection strategies","volume":"33","author":"Baumann","year":"2012","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.ghir.2024.101628_bb0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2265.1997.2111036.x","article-title":"Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH","volume":"47","author":"Kicman","year":"1997","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2024.101628_bb0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1677\/joe.0.1710163","article-title":"Administration of bovine, porcine and equine growth hormone to the horse: effect on insulin-like growth factor-I and selected IGF binding proteins","volume":"171","author":"De Kock","year":"2001","journal-title":"J. Endocrinol."},{"issue":"3","key":"10.1016\/j.ghir.2024.101628_bb0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/rvsc.2001.0505","article-title":"IGF-I plasma concentrations in non-treated horses and horses administered with methionyl equine somatotropin","volume":"71","author":"Popot","year":"2001","journal-title":"Res. Vet. Sci."},{"issue":"3","key":"10.1016\/j.ghir.2024.101628_bb0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1373\/clinchem.2008.112458","article-title":"High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports","volume":"55","author":"Bidlingmaier","year":"2009","journal-title":"Clin. Chem."},{"issue":"Suppl1","key":"10.1016\/j.ghir.2024.101628_bb0040","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.4103\/2230-8210.119494","article-title":"Detecting growth hormone misuse in athletes","volume":"17","author":"Holt","year":"2013","journal-title":"Ind. J. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2024.101628_bb0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ghir.2007.01.011","article-title":"Detection of growth hormone abuse in sport","volume":"17","author":"Powrie","year":"2007","journal-title":"Growth Hormon. IGF Res."},{"issue":"9156","key":"10.1016\/j.ghir.2024.101628_bb0050","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(99)00775-8","article-title":"Detection of doping with human growth hormone","volume":"353","author":"Wu","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ghir.2024.101628_bb0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1210\/clinem\/dgab799","article-title":"Application of the athlete biological passport approach to the detection of growth hormone doping","volume":"107","author":"Equey","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101628_bb0060","series-title":"Proceedings of the 18th International Conference of Racing Analysts and Veterinarians (ICRAV New Zealand)","first-page":"27","article-title":"Longitudinal follow-up on racehorses: veterinary and analytical issues. A one-year study of French trotters","author":"Duluard","year":"2010"},{"key":"10.1016\/j.ghir.2024.101628_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/dta.3795","article-title":"Bayesian individual limits for IGF-1 monitoring in equine plasma: implementation in the equine biological passport","author":"Barnabe","year":"2024","journal-title":"Drug Test. Anal."},{"issue":"9","key":"10.1016\/j.ghir.2024.101628_bb0070","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/dta.2180","article-title":"Intelligence-based anti-doping from an equine biological passport","volume":"9","author":"Cawley","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.ghir.2024.101628_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/dta.3770","article-title":"Intelligence-based anti-doping via an Intelligence and Drug Testing Management (IDTM) system","author":"Kwok","year":"2024","journal-title":"Drug Test Anal."},{"issue":"2","key":"10.1016\/j.ghir.2024.101628_bb0080","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/metabo12020146","article-title":"Investigations into the in vitro metabolism of hGH and IGF-I employing stable-isotope-labelled drugs and monitoring diagnostic immonium ions by high-resolution\/high-accuracy mass spectrometry","volume":"12","author":"Krombholz","year":"2022","journal-title":"Metabolites"},{"issue":"10","key":"10.1016\/j.ghir.2024.101628_bb0085","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/clinchem\/hvac119","article-title":"A targeted liquid chromatography\u2013tandem mass spectrometry Method FOR simultaneous quantification of peptides from the carboxyl-terminal region of Type III procollagen, biomarkers of collagen turnover","volume":"68","author":"Huynh","year":"2022","journal-title":"Clin. Chem."},{"issue":"21","key":"10.1016\/j.ghir.2024.101628_bb0090","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1021\/ac801234f","article-title":"Identification of recombinant equine growth hormone in horse plasma by LC\u2212 MS\/MS: a confirmatory analysis in doping control","volume":"80","author":"Bailly-Chouriberry","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ghir.2024.101628_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chroma.2016.11.032","article-title":"Simultaneous detection of recombinant growth hormones in equine plasma by liquid chromatography\/high-resolution tandem mass spectrometry for doping control","volume":"1478","author":"Wong","year":"2016","journal-title":"J. Chromatogr. A"},{"issue":"4","key":"10.1016\/j.ghir.2024.101628_bb0100","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cen.13409","article-title":"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial","volume":"87","author":"Battelino","year":"2017","journal-title":"Clin. Endocrinol."},{"issue":"44","key":"10.1016\/j.ghir.2024.101628_bb0105","doi-asserted-by":"crossref","first-page":"2101633","DOI":"10.1002\/adfm.202101633","article-title":"Protein engineering strategies for improved pharmacokinetics","volume":"31","author":"Rondon","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"2","key":"10.1016\/j.ghir.2024.101628_bb0110","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1038\/sj.ijo.0802746","article-title":"Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir","volume":"28","author":"Kurtzhals","year":"2004","journal-title":"Int. J. Obes."},{"issue":"9548","key":"10.1016\/j.ghir.2024.101628_bb0115","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ghir.2024.101628_bb0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41573-022-00529-w","article-title":"Derivatization with fatty acids in peptide and protein drug discovery","volume":"22","author":"Kurtzhals","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ghir.2024.101628_bb0125","author":"IFHA"},{"key":"10.1016\/j.ghir.2024.101628_bb0130","author":"WORLD ANTI-DOPING CODE"},{"key":"10.1016\/j.ghir.2024.101628_bb0135","author":"AORC"},{"issue":"1","key":"10.1016\/j.ghir.2024.101628_bb0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/btpr.72","article-title":"Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone","volume":"25","author":"Jiang","year":"2009","journal-title":"Biotechnol. Prog."},{"issue":"9","key":"10.1016\/j.ghir.2024.101628_bb0145","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/jms.891","article-title":"Fragmentation reactions of deprotonated peptides containing proline. The proline effect","volume":"40","author":"Harrison","year":"2005","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ghir.2024.101628_bb0150","article-title":"A combined top-down and bottom-up LC-HRMS\/MS method for the quantification of human growth hormone in plasma and serum","volume":"101560","author":"Krombholz","year":"2023","journal-title":"Growth Hormon. IGF Res."},{"issue":"4","key":"10.1016\/j.ghir.2024.101628_bb0155","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2527\/1996.744886x","article-title":"The effects of bovine somatotropin (bST) and porcine somatotropin (pST) on growth factor and metabolic variables in horses","volume":"74","author":"Buonomo","year":"1996","journal-title":"J. Anim. Sci."},{"key":"10.1016\/j.ghir.2024.101628_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106030","article-title":"Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects","volume":"167","author":"Helleberg","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ghir.2024.101628_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106032","article-title":"Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats","volume":"168","author":"Helleberg","year":"2022","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637424000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637424000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T03:50:33Z","timestamp":1741578633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637424000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"alternative-id":["S1096637424000583"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2024.101628","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and differentiation of somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone in equine plasma by LC-HRMS for doping control purpose","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2024.101628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101628"}}